UTOLA: UTerin OLAparib

Summary

This is a phase IIB, national, randomized, double-blinded, comparative, multi-center study, to assess the efficacy of Olaparib as maintenance after a platinum based chemotherapy in patients with Advanced or metastatic endometrial cancer

Timeline

Start

2019-02-01

Primary completion

2023-05-22

Completion

2024-09-24

Publications

• Beinse G, Leroy K, Just PA, Jeanne C, Cherifi F, Leary A, Le Saux O, You B, Rodrigues M, Gladieff L, Abadie-Lacourtoisie S, Lefevre LB, Brachet PE, Lebreton C, Meynard G, Fournel P, Frenel JS, Selle F, Largillier R, Foa C, Cornila C, Fernandez Diez Y, Bonnet E, Arnaud A, Kaczmarek E, Follana P, Bouchaert P, Joly F, Alexandre J, Leman R. Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial. Int J Gynecol Cancer. 2026 Feb;36(2):102829. doi: 10.1016/j.ijgc.2025.102829. Epub 2025 Nov 21.

Drugs

Indications